Stelic Institute & Co., a Tokyo-based bioventure company specializing in regenerative medicine, has announced development of a new treatment method for acute liver failure: The Company's Stem Cell Dynamism Research Team has shown that a protein called chemokine1 CXCL102 directly affects hepatic cells, regulating their replication and proliferation. Research results demonstrated for the first time that hepatic cells possess a mechanism for attempting to repair the wide-ranging hepatic cell necrosis associated with drug-induced acute liver failure, and that anti-CXCL10 antibodies strengthen this type of self-repairing function at the in vivo level.
More information via www.stelic.com

Comments